We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
78 hedge funds and large institutions have $220M invested in Crescent Biopharma in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
90% more call options, than puts
Call options by funds: $74K | Put options by funds: $39K
22% more capital invested
Capital invested by funds: $180M → $220M (+$40.3M)
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
4% more funds holding
Funds holding: 75 → 78 (+3)
0.01% less ownership
Funds ownership: 0.96% → 0.96% (-0.01%)
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Holders
78
Holders Change
+3
Holders Change %
+4%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
17
Increased
21
Reduced
27
Closed
14
Calls
$74K
Puts
$39K
Net Calls
+$35K
Net Calls Change
-$26K
Top Buyers
Top Sellers
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$3.54M |
| 2 |
Millennium Management
New York
|
-$829K |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$819K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$717K |
| 5 |
BlackRock
New York
|
-$549K |
